Hyun Woo Lee

Hyun Woo Lee

Auto-generated profile, based on publicly available information

Hyun Woo Lee

Department of Internal Medicine, Gimpo Woori Hospital, Gimpo, Korea

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2020 in Gut and Liver
Verified
Journal Article
Open access
PDF file
HLHyun Woo Lee
Hyun Woo Lee
SLSung Koo Lee
Sung Koo Lee
JJJae Hyuck Jun
Jae Hyuck Jun
TSTae Jun Song
Tae Jun Song
Do Hyun ParkDo Hyun Park
Do Hyun Park
MKMyung-Hwan Kim
Myung-Hwan Kim
Hyun Woo Lee, Sung Koo Lee, Jae Hyuck Jun, Tae Jun Song, Do Hyun Park, Sang Soo Lee, Dong-Wan Seo, and Myung-Hwan Kim. Gut and Liver 2020;14:248-56. https://doi.org/10.5009/gnl18488

22 June 2026 in Gut and Liver
Verified
Journal Article
Open access
SKSang Gyun Kim
Sang Gyun Kim
TKTae-Oh Kim
Tae-Oh Kim
SJSung Woo Jung
Sung Woo Jung
BMByung-Hoon Min
Byung-Hoon Min
JOJUNG HWAN OH
JUNG HWAN OH
JKJae J. Kim
Jae J. Kim
Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) increases the risk of peptic ulcers. Tegoprazan, a novel potassium-competitive acid blocker, provides rapid and potent inhibition of acid production. This study evaluated whether tegoprazan 25 mg is non-inferior to lansoprazole 15 mg in preventing NSAID-induced peptic ulcer. In this double-blind, randomized, active-controlled, multicenter phase III trial, patients requiring NSAIDs for up to 24 weeks were randomized (1:1) to the tegoprazan or the lansoprazole group. The primary endpoint was the incidence of peptic ulcer at week 24 in the per-protocol population. Secondary endpoints were NSAID-induced gastrointestinal symptom-free rates. Safety outcomes included adverse drug reactions (ADRs) and serious adverse events (SAEs). A total of 392 patients were randomized, and 269 patients were analyzed in the perprotocol set. Tegoprazan was non-inferior to lansoprazole for the prevention of gastroduodenal ulcers (p=0.0004). The heartburn-free rate at week 12 was higher in the tegoprazan group (p=0.0421), while other symptom-free rates did not differ significantly. In terms of safety, ADR and SAE rates were comparable and not significantly different. Tegoprazan was non-inferior to lansoprazole in preventing NSAID-induced peptic ulcers with excellent tolerance. Tegoprazan represents a clinically effective alternative gastroprotective therapy (ClinicalTrials.gov identifier NCT04840550).